Halozyme Therapeutics (HALO) Leases (2019 - 2025)
Historic Leases for Halozyme Therapeutics (HALO) over the last 8 years, with Q3 2025 value amounting to $30.8 million.
- Halozyme Therapeutics' Leases fell 1063.05% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year decrease of 1063.05%. This contributed to the annual value of $34.2 million for FY2024, which is 723.48% down from last year.
- Halozyme Therapeutics' Leases amounted to $30.8 million in Q3 2025, which was down 1063.05% from $31.9 million recorded in Q2 2025.
- Halozyme Therapeutics' 5-year Leases high stood at $40.5 million for Q4 2022, and its period low was $1.6 million during Q1 2022.
- For the 5-year period, Halozyme Therapeutics' Leases averaged around $23.7 million, with its median value being $32.6 million (2025).
- In the last 5 years, Halozyme Therapeutics' Leases crashed by 4927.3% in 2022 and then surged by 241082.8% in 2023.
- Over the past 5 years, Halozyme Therapeutics' Leases (Quarter) stood at $2.0 million in 2021, then skyrocketed by 1920.42% to $40.5 million in 2022, then fell by 8.98% to $36.8 million in 2023, then dropped by 7.23% to $34.2 million in 2024, then dropped by 9.73% to $30.8 million in 2025.
- Its Leases was $30.8 million in Q3 2025, compared to $31.9 million in Q2 2025 and $32.6 million in Q1 2025.